Uber stock surges after Nvidia partnership announcement
Eric Swayze, Executive Vice President of Research at Ionis Pharmaceuticals Inc (NASDAQ:IONS), sold 53 shares of common stock at a price of $73.6213 on October 16, 2025, for a total of $3901. The transaction occurs as the stock trades near its 52-week high of $74.42, with InvestingPro data showing an impressive 157% return over the past six months.
On October 15, Swayze also acquired 125 shares of Ionis Pharmaceuticals stock, valued at $0, and disposed of 125 Restricted Stock Units. These shares were acquired through the vesting and release of shares from a Restricted Stock Unit award.
Following these transactions, Swayze directly owns 30,453 shares of Ionis Pharmaceuticals Inc. common stock. He also indirectly owns 256 shares by Son.
In other recent news, Ionis Pharmaceuticals reported a notable increase in revenue for the second quarter of 2025, with figures doubling year-over-year to reach $452 million. This significant growth has led the company to revise its 2025 revenue guidance upwards, now expecting between $825 million and $850 million. This adjustment indicates the company’s confidence in its ongoing product launches and developments within its pipeline. The earnings results mark a critical development for investors monitoring Ionis Pharmaceuticals’ financial performance. While the company’s stock experienced a minor increase, the focus remains on its financial results and future projections. These recent developments have captured the attention of investors and analysts alike, highlighting Ionis Pharmaceuticals’ strategic growth and potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.